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Abstract In this paper I will review different aspects of
genetic risk in the context of preconception care. I restrict
myself to the knowledge of risk which is relevant for care
and/or enables reproductive choice. The paper deals with
chromosomes, genes and the genetic classification of
diseases, and it explains why Mendelian disorders frequent-
ly do not show the expected pattern of occurrence in
families. Factors that amplify genetic risk are also dis-
cussed. Of the two methods of genetic risk assessment—
history taking and genetic screening—the former method is
examined to some extent, and the consequences of an
inadequate family history are illustrated in a case report.
The paper ends with a review of the sparse literature
available on the frequency of a positive family history and
an outline of the challenges and rewards faced by
professionals when confronted with a positive history.
Introduction
Genetic factors are of paramount importance for normal
development and health. Abnormal genes and abnormal
expression of genes may therefore lead to birth defects and
diseases. Although the same applies for many exogenous
factors, I focus here on the genetic ones. A further focus
will be on genetic factors whose knowledge is of relevance
for reproductive choice. Psychological and ethical issues
will be discussed in the papers by Riedijk et al. (this issue)
and De Wert et al. (this issue); future methods of genetic
risk assessment will be discussed in the paper by Ropers
(this issue).
Relevance of knowledge of genetic risk
Two main reasons for identifying genetic risk in the
preconception period are that preconception knowledge of
genetic risk may influence care and also may allow
informed reproductive choice. Knowledge of genetic risk
may influence preconception care, prenatal care, mode of
delivery and postnatal care. Previous birth of a child with a
neural tube defect—a multifactorial genetic condition—
indicates a higher dose of folic acid supplementation
preconceptionally and in the first months of pregnancy,
than for a woman without neural tube defects in her family
(Grosse and Collins 2007). Preeclampsia in a sister of a
pregnant woman leads to a higher level of alertness for
related symptoms during prenatal care. Dexamethasone
treatment in an unborn sib of a child with congenital
adrenal hyperplasia has to start as soon as the pregnancy is
confirmed, well before invasive prenatal diagnosis of the
foetus is possible (Nimkarn and New 2010).
Preconception knowledge of genetic risk also allows
informed reproductive choice. Consider a couple in which
both partners are carriers of an autosomal recessive disease
like cystic fibrosis. What options do they have? If they
conceive normally, the child will have a 25% risk of being
affected by this disease. The couple may decide to take the
risk and only find out whether the child is affected after its
birth, or they may consider prenatal diagnosis. If they opt
for prenatal diagnosis and the foetus turns out to be
affected, they must decide whether to continue or to
terminate the pregnancy. However, they also may decide
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not to become pregnant in the usual way, but to make use of
in vitro fertilization with embryo selection, or to choose
artificial insemination with donor sperm or egg cells. Of
course the couple can also decide to stay childless or to
adopt children. Even splitting up is an option.
It is clear that the number of reproductive options in the
preconception phase is much bigger than after conception.
It is also clear that these are not easy decisions to make and
that every possible effort should be made to ensure that the
decision of the couple is based on the principle of informed
choice. Identifying a high genetic risk in a couple also has
consequences for family members. In what follows I will
focus mainly on genetic risk factors that are relevant for
reproductive choice.
Chromosomes and genes
There are many excellent textbooks dealing with medical
genetics and genetic diseases. Here I will summarise what
is customary knowledge. For details, please consult the
appropriate text books.
Every normal human being has 23 pairs of chromosomes
in the nucleus of almost all cells of the body. One copy of
each pair is of paternal origin, and the other one is
maternally derived. One pair of the 23 chromosome pairs
is different in males (XY) and females (XX). The other 22
paired chromosomes are called autosomes.
Approximately 25,000 genes are aligned along the
chromosomes. On the autosomes there are always two
copies of each gene (one on the paternally derived
chromosome and one on its maternal counterpart). The
same applies to the X chromosomes in females. In males
there are different genes on the X and the Y chromosome,
apart from a region called the pseudo-autosomal region. So,
for most of the genes on the X and Y chromosome, males
have only one copy. Egg cells and sperm cells have 23
single chromosomes, one copy of each pair. Red blood cells
have lost their nucleus and with it their chromosomes. In
addition to the approximately 25,000 genes on the
chromosomes in the single nucleus of the cell, the many
mitochondria in the cell each contain 37 genes.
Apart from the importance of genes for normal devel-
opment and health, variation within genes is also respon-
sible for the large variation between persons, which is what
makes each of us genetically unique. Considering individ-
ual copies of genes, a practical distinction is between
‘normal’ genes (the wild type in biology) and altered or
mutated genes with an observable effect on the phenotype
including health and disease. The focus in this paper is on
detrimental or pathogenic mutations. We must however
realize that there are mutations that are detrimental in one
situation, and neutral or even beneficial in other circum-
stances. For instance, while a particular mutation in the β-
globin gene causes sickle cell disease when both copies of
the gene are altered, it protects against malaria when the
mutation is present in a single dose. Nevertheless, in what
follows, I will use the words mutation and mutated in the
negative sense, unless otherwise specified.
Mutations may be restricted to a particular gene or
involve many adjacent genes or even complete chromo-
somes. Some mutations have only a very small effect,
which only becomes manifested in conjunction with small
effect mutations in many other genes and under certain
environmental conditions, as in so-called multifactorial
disorders; other mutations have a very big effect and
become manifested even if present in a single dose; other
mutations again are situated somewhere in between these
two extremes. Mutations which are manifested even in a
single dose are called dominant; mutations which only
become manifested in a double dose but not in a single dose
are called recessive. Mutations may be new, i.e., not present
in the parents of the person with the mutation or inherited, i.e.,
present in at least one of the parents. Some mutations are
present in only a proportion of all cells of a person, a
phenomenon known as mosaicism.
An important distinction is made between phenotype and
genotype. A person’s phenotype is what we can observe,
without having to study his or her chromosomes or genes.
Genes and chromosomes belong to a person’s genotype.
For instance the disease cystic fibrosis (phenotype) can be
diagnosed from its clinical presentation combined with a
high concentration of salt in the patient’s sweat. The disease
is caused by the presence of a mutation in both copies of
the so-called CFTR gene (genotype). Both terms may be
used in a restrictive sense (one phenotypic aspect or one
particular gene) and in a general one (the totality of one’s
phenotype or the totality of one’s chromosomes and genes).
Genetic classification of diseases
Table 1 summarises the major modes of inheritance of
human variation. Patients with numerical chromosomal
disorders have either more or less than the usual number
of 46 chromosomes. Figure 1 shows the chromosomal
constitution of a male Down syndrome patient with trisomy
21. Patients with unbalanced structural abnormalities
may have the normal number of chromosomes, but they
lack parts of chromosomes or have parts in excess.
Carriers of balanced structural abnormalities are in
general phenotypically normal (see Fig. 2). They may
however produce offspring with an unbalanced chromo-
somal constitution. It is difficult to recognize a chromo-
somal disorder just from the pattern of occurrence of
affected persons in the family.
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Monogenic disorders are also called Mendelian disorders
as they follow the Mendelian rules of inheritance. Autosomal
dominant diseases for instance may show a characteristic
pattern within pedigrees, showing vertical transmission, equal
occurrence in males and females, transmission probability of
50% and father-to-son transmission. Autosomal recessive
diseases show one or more affected sibs of either sex in a
family and rare instances of affected persons elsewhere in the
family. X-linked recessive diseases may show a pattern of
occurrence in males only and transmission through unaffected
females in the pedigree. Mitochondrial diseases may at first
sight seem to present as an autosomal dominant disease, but
affected males never have affected offspring, as mitochondria
are not transmitted through sperm cells. A word of warning
should be given here as the situations in which it is possible to
recognize the pattern of inheritance just by simple inspection
Fig. 1 Chromosomal constitution of a male Down syndrome patient with trisomy 21 (courtesy of A. Nieuwint, Cytogenetic Laboratory, VU
University Medical Center, Amsterdam, the Netherlands)
Table 1 Classification of genetic diseases
Genotype Example of disease (phenotype)
Major categories Subcategories
Chromosomal disorders Numerical Down syndrome
Structural Unbalanced Partial deletion
Balanced –
Monogenic disorders Autosomal Dominant Neurofibromatosis
Recessive Cystic fibrosis
X chromosomal Dominant Rett syndrome
Recessive Duchenne muscular dystrophy
Mitochondrial disorders Leber optic neuropathy
Multifactorial and complex disorders Neural tube defects, cleft lip, several
chronic diseases
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of the pedigree are rare, even when a Mendelian or
mitochondrial disorder is present. Real life is much more
complicated than textbook pictures claim.
Multifactorial diseases are caused by an accumulation of
many mutations of small effect and environmental factors
in the affected person. It is difficult to recognize a
multifactorial disease just from the pattern of affected
members in the family. Complex diseases combine cases
with a multifactorial inheritance and with a monogenic or
mitochondrial aetiology. Good examples of this are
diabetes, cancer and cardiovascular diseases.
Why Mendelian disorders frequently do not show
the expected pattern of occurrence in families
There are many factors which can complicate the expected
pattern of occurrence of a Mendelian disorder in a family. I
will mention some of them here, without claiming to
present a complete picture.
When a given genotype always gives rise to an
observable effect in a person’s phenotype, we say that
the penetrance of the genotype is complete. If the
genotype leads to an observable effect in less than
100% of the cases, the penetrance is referred to as
being incomplete. Incomplete penetrance may for in-
stance give rise to the phenomenon known as skipping
of a generation in a family with a well-known
autosomal dominant disorder. Figure 3 shows a recently
reported example of incomplete penetrance.
Fig. 2 Chromosomal constitution of a female person with a balanced translocation between chromosome 1 and chromosome 7 (courtesy of A.
Nieuwint, Cytogenetic Laboratory, VU University Medical Center, Amsterdam, the Netherlands)
Fig. 3 Pedigree of a family with Charcot–Marie–Tooth disease, a
hereditary neuropathy. Filled symbols are affected persons. They have
a mutation in the so-called TRPV4 gene. Symbols with plus sign
represent unaffected carriers of the same mutation. Symbols with
minus sign are persons without this mutation. As only three out of the
six persons with the mutation are affected, penetrance in this pedigree
is 50% (redrawn and slightly modified from Berciano et al. 2011)
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Another reason why it may be difficult to deduce the
pattern of inheritance directly from its occurrence in a
family is the phenomenon of variable expressivity. By
this we mean that a given genotype may lead to
different clinical pictures in different persons. One may
then assume that there are several different disorders in
the family, while in fact the disorders in the family
members have the same underlying genetic cause.
Figure 4 shows a recently reported example of variable
expressivity.
When two parents are carriers of an autosomal
recessive disease, each child has a 25% chance of
developing that particular disease, but this also means a
75% chance of not developing the disease. If the
parents have two children, there is a 56% chance that
none of them has the disease. With three children there
is still a 42% chance that all will be free of the disease
and so on. The chance that at least two children will be
affected, thereby indicating the familial nature of the
disease, is only 6% in a two-child family, 16% in a
three-child family, 26% in a four-child family and so
on. With smaller family sizes, the probability that an
autosomal recessive disorder within a family is recog-
nized as familial is therefore rather limited. To a lesser
extent, the same restriction applies to a patient who is
the first one with an autosomal dominant disorder in the
family, when this person has only one child or just a
few children.
There are several possible reasons why a person with
an autosomal dominant disease may be the first to show
this disease in the family. The disorder may be due to a
new mutation, but it may also be that one of the parents
already carries the mutation, either in all his or her
cells, or as a mosaic. The reason for not showing the
disease if a parent carries the mutation in all cells can
be a matter of incomplete penetrance or due to variable
expressivity. In some disorders, whether or not a
mutation is expressed, can depend on the sex of the
parent who transmitted the mutation (so-called imprint-
ing). There are also dominant and other diseases in
which penetrance and expression increase from genera-
tion to generation (so-called anticipation). In this case a
seemingly harmless mutation (called a premutation)
develops into a full mutation by passage to the following
generation.
An autosomal dominant disorder may also mimic the
pattern we would expect from a recessive disease, for
instance when a phenotypically normal person who is
mosaic for an autosomal dominant mutation has two
affected children. Conversely, an autosomal recessive
disease may mimic the pattern of a dominant disorder,
when the partner of a patient is a carrier of the same
disorder (pseudo dominance). This situation is only
possible when the severity of the disease does not prohibit
reaching adulthood and procreation.
Although incomplete, this review of complications
hindering a straightforward interpretation of the occurrence
of a disorder in a family is meant to illustrate our earlier
warning: situations in which you can recognize the pattern
of inheritance just by simple inspection of the pedigree are
rare, even when a Mendelian or mitochondrial disorder is
present. The fact that only one person in a family is affected
or that the pattern of occurrence in a family does not
comply with a well-known pattern of inheritance can
never exclude a genetic aetiology or a genetic risk to
family members. This has important implications for
risk assessment in the preconceptional phase, as we will
see later on.
Amplification of genetic risk
There are a number of situations which may increase
genetic risk. New mutations are more frequent in the
offspring of parents of advanced age than in younger
parents. The most well-known situation is the increased risk
for Down syndrome and some other numerical chromo-
somal anomalies with maternal age. For some autosomal
dominant mutations, a correlation with advanced paternal
age has been demonstrated too. Originally, the increased
risk for Down syndrome constituted an indication for
prenatal diagnosis for pregnant women at advanced age,
but nowadays, this policy has been replaced widely by the
offer of prenatal screening of all pregnant women,
irrespective of their age. As new mutations leading to
dominant diseases are much rarer than Down syndrome,
advanced paternal age has not been a reason for invasive
prenatal diagnosis so far.
Fig. 4 Pedigree of a family with different manifestations of the
presence of a mutation in the FGFR1 gene (symbols with plus
sign) in three family members (redrawn and slightly modified from
Au et al. 2011)
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In addition to parental age, contact with ionizing
radiation or mutagenic agents, either in the medical or
occupational situation, has to be considered. This will be
covered in the paper by Mulvihill (this issue).
The risk of autosomal recessive disorders is greatly
increased by consanguineous marriage. This subject will
be dealt with in the paper by Hamamy (this issue).
If partners of a couple both originate from a place known
for a high frequency of a particular autosomal recessive
disease, their risk for that disorder may also be increased,
even if there is no known close consanguinity between the
partners. In a wider context, this also applies to partners
from the same clan or with the same ethnic background.
Sickle cell anaemia and thalassaemias are more frequent in
persons whose ancestors came from Africa, the Mediterra-
nean area, and countries in Southern and Western Asia,
while cystic fibrosis is more frequent in persons with
ancestors in Europe and the Mediterranean area (Fig. 5).
Finally we may consider poor health care and genetic
illiteracy as factors that contribute to genetic risk in
families subject to these conditions, since recognition of
genetic risk requires an appropriate diagnosis and
sufficient knowledge of the genetics of the disorder in
the family.
Genetic risk assessment
There are two approaches to assess genetic risk. The first
one involves taking a careful medical history of the couple
and their family (see the paper by Bennett in this issue), and
the second one is through genetic screening (see the paper
by Metcalfe in this issue).
As I have argued above, a clear-cut pattern of occurrence
of a disease in the family is rather rare, so we have to base
our medical history taking on other principles:
1. Every health problem in one of the partners or in a
family member, either at present or in the past, may
have a genetic basis, unless there are good argu-
ments to refute this possibility. As stated before, the
absence of a second patient with the disorder in the
family is never a valid argument against a genetic
aetiology.
2. Inquiring about the presence of a genetic disorder in the
family or presenting a list of disorders that might be
genetic is a sure way to miss important risks as
knowledge on whether a given disorder is genetic
within a family cannot be presumed and since lists of
disorders that may be genetic can never be complete
Fig. 5 Global distribution accord-
ing to ancestry of patients and
carriers of cystic fibrosis (in blue)
and the hemoglobinopathies
(sickle cell disease and thalassae-
mias), (in red); (courtesy of Dr. P.
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enough. Therefore it is recommended to ask for each
person in the family individually about his or her
present and past health, including whether he or she
was ever admitted to hospital and for what reason. This
questioning can also be done by means of a written
questionnaire or an electronic aid.
3. The surest way to detect genetic risk is to obtain a
medical diagnosis for each health problem in the family
and to check whether this diagnosis is known to point
to a genetic risk. This may involve asking the
permission of the patient to question his or her
physician about the nature of the disorder and to
consult someone with expert knowledge on the genetics
of the disorder, or even to refer the couple or the patient
to such an expert for further workup (see the paper by
Read and Donnai in this issue).
4. Since family histories are dynamic, they need to be
updated again and again (American College of Obste-
tricians and Gynecologists Committee on Genetics
2011; Ziogas et al. 2011).
The sad story of Peter S.
Peter S. was 10 months old when his parents became aware
that the pupil of his left eye appeared pale on pictures made
with flashlight (see Fig. 6). At the age of 15 months, he was
referred to a local ophthalmologist, who suspected retino-
blastoma and sent him to an expert centre. Here the
diagnosis was confirmed, and his left eye was enucleated,
since the tumour was too far advanced to warrant more
conventional interventions. During the workup it became
apparent that the father’s left eye had been enucleated when
he was very young too, also due to a retinoblastoma. It
turned out that this diagnosis was not known to this man or
to his parents and that the possibility of a genetic aetiology
had never been discussed with them. During his wife’s
pregnancy, no one had ever raised the possibility that the
husband’s history of an eye tumour might need closer
examination. He was the first one in the family with this
problem, and ideally, he should have been referred earlier
for genetic testing as 15% of nonfamilial unilateral cases of
retinoblastoma concern carriers of a mutation in the
retinoblastoma gene. Besides the eye tumour and the
reproductive risk, carriers of a retinoblastoma mutation
have an increased risk of other tumours and should be
checked regularly. Besides other options (Dommering et al.
2010), one option for carriers of a retinoblastoma mutation
is to have their children tested very soon after birth and to
closely monitor those with a mutation, to enable an
intervention with more conventional means as soon as a
tumour develops. If this had been done in this case, Peter
would probably still have his eye.
How frequent is a positive family history?
Although there is wide consensus in literature about the
importance of taking a medical family history for precon-
ception care, data on the frequency of a positive family
history are scant. The largest population studied was
reported by Meschede et al. (2000), who analyzed the yield
of pedigree analysis in 1,356 consecutive genetic counsel-
ling sessions of women considering invasive prenatal
diagnosis for advanced maternal age or an abnormal result
upon triple serum marker screening, and without a
secondary indication for genetic counselling. They found
108 cases (8%) with a total of 117 disorders which they
regarded as both relevant and significant. To be considered
relevant, a disorder had to be manifesting congenitally or
during childhood in the majority of cases and to have a
major impact on the quality of life. A relevant disorder was
considered significant if, after genetic workup the risk to
the foetus was estimated to be 0.5% or higher. Besides
these relevant and significant disorders in the family, there
were 23 cases in which one of the partners had a disorder
qualifying as relevant and significant, and in 16 cases, there
was significant consanguinity (at least second cousins).
Adding these numbers up, 147 cases (11%) had a relevant
and significant risk. As this percentage is the result of
interpretation and follow-up studies, the real frequency of
disorders mentioned in response to taking a family and
personal medical history must have been many times
greater, suggesting a considerable workload.
Van der Pal-de Bruin et al. (2008) reported on the
prevalence of risk factors in preconception counselling of
Fig. 6 Peter S. and his father. Notice the reflection in Peter’s eye
(published with written consent of Peter’s father)
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481 couples in primary care practices. In 42% of these
couples, family history required further action by the
general practitioner (GP). In 4%, following counselling by
the GP, referral to a clinical genetics centre was indicated.
In 38% of cases, more information was needed before a
decision could be made as to whether referral to a
specialist had to be considered. The authors recognize
the possibility of bias introduced if the participating
couples were a selected group with a higher frequency
of reproductive risk factors. Since this may also apply
to couples coming for preconception counselling in the
future, it is safe to say that a considerable proportion of
couples qualifying for preconception care have genetic
risk factors in their personal and family history and
deserve an adequate response.
Challenge and reward
The above sad story of Peter S. is a perfect illustration
of the importance of an adequate family history and an
appropriate follow-up of that history. It is possible that
history taking by the professionals attending this family
was inadequate, leading to the surgery for an eye
tumour at a young age in the father to be being missed.
It is also possible that they were aware of the eye
tumour but failed to identify precisely what had
happened or to establish the possible consequences of
the precise diagnosis.
Taking a family history implies a commitment to follow-up
on that history in two directions: what is the precise diagnosis
and what are the consequences of that diagnosis for this
couple. The levels of competences of primary care profes-
sionals in these matters are probably highly variable, which
implies that consulting with a colleague with more expertise
on the particular subject or referral is a wise policy.
Given the numbers of relevant and significant disorders
in the family histories of preconception couples, combined
with the numbers for which more information is needed
before a decision can be made, genetic risk assessment in
preconception consultation is a real challenge. However,
the results of this effort can be very rewarding for the
couple, their children and other family members, and for
the professional involved.
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